The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparison of outcomes between patients of African and European descent with metastatic renal cell carcinoma receiving immune checkpoint inhibitors.
 
Jasmeet Kaur
No Relationships to Disclose
 
Jill S. Hasler
Patents, Royalties, Other Intellectual Property - Patent pending for Machine Learning Systems using Electronic Health Record Data and Patient Reported Outcomes
 
Elizabeth A. Handorf
Honoraria - NCCN/Pfizer
Research Funding - NCCN/Lilly (Inst)
 
Matthew R. Zibelman
Honoraria - Pfizer
Consulting or Advisory Role - AVEO; Blue Earth Diagnostics; EMD Serono; Exelixis; Janssen; Merck; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Horizon Pharma (Inst)
Travel, Accommodations, Expenses - DAVA Oncology
 
Daniel M. Geynisman
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Exelixis; Merck; Myovant Sciences; Pfizer; Seattle Genetics/Astellas
Research Funding - Astellas Pharma (Inst); Calithera Biosciences (Inst); Genentech (Inst); Harpoon therapeutics (Inst); Merck (Inst)
 
Elizabeth R. Plimack
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Medarex; Eisai; EMD Serono; Exelixis; Flagship Pioneering; IMV; Merck; Pfizer; Regeneron; Seagen; Signatera; Synthekine
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst)
 
Pooja Ghatalia
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb Foundation (Inst); Merck (Inst)